{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080805","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.586273+00:00","generated_at":"2026-06-13T09:10:10.258468+00:00","sec_items":["1.01","2.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Applied DNA acquires Spindle Biotech for $625K cash + stock; launches LineaIVT mRNA platform","bullets":["Total consideration: $625K cash, 750K restricted shares, up to 1M earn-out shares, and 10-year revenue share.","Spindle's RNA polymerase combined with Applied DNA's linearDNA templates reduces dsRNA contamination in mRNA production.","Aaron Chung, Spindle co-founder and CEO, joins Applied DNA as Director of Nucleic Acid Platforms.","LineaIVT platform launched with early access program; targets >20% of mRNA manufacturing COGS.","Transaction accounted for as asset acquisition; financials consolidated from July 12, 2023 closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080805","json":"https://secwatch.observer/filing/0001104659-23-080805.json","markdown":"https://secwatch.observer/filing/0001104659-23-080805.md","text":"https://secwatch.observer/filing/0001104659-23-080805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465923080805/0001104659-23-080805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465923080805/tm2321212d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:10:10.258468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0ecf30343e413fe1a7cf1fd84a6e13a6bab1ba3","claim":"BNB PLUS CORP. completed an acquisition involving Spindle Biotech Inc. for cash of $625,000 and 750,000 restricted shares of common stock, plus potential earn-out (closed 2023-07-12).","evidence_excerpt":"the transactions contemplated by the Purchase Agreement, the Purchaser agreed to pay or issue to the Sellers, as applicable, on a pro rata basis: (i) a cash purchase price of $625,000, as adjusted for debt of Spindle as of the closing date and expenses related to the transaction, which was paid to the Sellers on the Closing Date; (ii) 750,000 restricted shares","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465923080805/0001104659-23-080805-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Spindle Biotech Inc."},{"label":"Consideration","value":"cash of $625,000 and 750,000 restricted shares of common stock, plus potential earn-out"},{"label":"Closing","value":"2023-07-12"}],"fact_type":"ma_transaction"},{"claim_id":"13760f419c4851bcdc7353d2fc0fef0a5f8ae2f1","claim":"BNB PLUS CORP. entered into Share Purchase Agreement with Spindle Biotech Inc., the Sellers, and Lai Him Chung valued at $625,000 (effective 2023-07-12).","evidence_excerpt":"On July 12, 2023 (the “Closing Date”), Spindle Acquisition Corp., a corporation existing under the laws of the Province of Ontario (the “Purchaser”), and a wholly-owned subsidiary of Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with Spindle Biotech Inc., a corporation existing under the federal laws of Canada (“Spindle”), the persons listed on Schedule 1.1 of the Purchase Agreement (the “Sellers”) and Lai Him Chung, as Seller Representative.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465923080805/0001104659-23-080805-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Spindle Biotech Inc., the Sellers, and Lai Him Chung"},{"label":"Value","value":"$625,000"},{"label":"Effective","value":"2023-07-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}